UCB (OTCMKTS:UCBJF) Trading Down 6.2% – Time to Sell?

UCB SA (OTCMKTS:UCBJF) shares were down 6.2% during trading on Friday . The stock traded as low as $284.3501 and last traded at $284.3501. Approximately 6 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 698 shares. The stock had previously closed at $303.29.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on UCBJF. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of UCB in a report on Monday, December 8th. The Goldman Sachs Group restated a “buy” rating on shares of UCB in a research note on Monday, February 16th. Barclays reaffirmed an “overweight” rating on shares of UCB in a research note on Tuesday, January 6th. Stephens reiterated an “overweight” rating on shares of UCB in a report on Thursday, January 15th. Finally, Wolfe Research initiated coverage on UCB in a research report on Monday, February 23rd. They set an “outperform” rating for the company. Six investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy”.

UCB Trading Down 1.5%

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The firm has a 50 day moving average of $311.67 and a two-hundred day moving average of $286.10.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.